Whom is going to take this and create a human research trial? ASA, NSA? Never, we need our great stroke association.
Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats
Source
Department of Neurology, Henry Ford Health Sciences Center, Henry Ford Hospital, Detroit, Michigan, USA.Abstract
Here,
for the first time, we test a novel hypothesis that systemic treatment
of stroke with exosomes derived from multipotent mesenchymal stromal
cells (MSCs) promote neurovascular remodeling and functional recovery
after stroke in rats. Adult male Wistar rats were subjected to 2 hours
of middle cerebral artery occlusion (MCAo) followed by tail vein
injection of 100 μg protein from MSC exosome precipitates or an equal
volume of vehicle phosphate-buffered saline (PBS) (n=6/group) 24 hours
later. Animals were killed at 28 days after stroke and histopathology
and immunohistochemistry were employed to identify neurite remodeling,
neurogenesis, and angiogenesis. Systemic administration of MSC-generated
exosomes significantly improved functional recovery in stroke rats
compared with PBS-treated controls. Axonal density and
synaptophysin-positive areas were significantly increased along the
ischemic boundary zone of the cortex and striatum in MCAo rats treated
with exosomes compared with PBS control. Exosome treatment significantly
increased the number of newly formed doublecortin (a marker of
neuroblasts) and von Willebrand factor (a marker of endothelial cells)
cells. Our results suggest that intravenous administration of cell-free
MSC-generated exosomes post stroke improves functional recovery and
enhances neurite remodeling, neurogenesis, and angiogenesis and
represents a novel treatment for stroke.Journal of Cerebral Blood Flow
& Metabolism advance online publication, 21 August 2013;
doi:10.1038/jcbfm.2013.152.
No comments:
Post a Comment